• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases.

作者信息

Melicine Sophie, Billoir Paul, Faille Dorothée, Grove Erik Lerkevang, Lê Minh P, Ajzenberg Nadine, Smadja David M, Gendron Nicolas

机构信息

Hematology Department, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, Paris, France.

Unité d'hémostase vasculaire, UNIROUEN, INSERM U1096, Normandie Univ, Hôpital Universitaire Rouen, Rouen, France.

出版信息

Res Pract Thromb Haemost. 2023 Jun 8;7(5):100201. doi: 10.1016/j.rpth.2023.100201. eCollection 2023 Jul.

DOI:10.1016/j.rpth.2023.100201
PMID:37601026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10439387/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e73/10439387/33a384744157/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e73/10439387/743d9be0a880/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e73/10439387/33a384744157/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e73/10439387/743d9be0a880/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e73/10439387/33a384744157/gr1.jpg

相似文献

1
Dabigatran-reversal failure using standard dose of idarucizumab: a systematic review and meta-analysis of cases.使用标准剂量艾达赛珠单抗进行达比加群逆转失败：病例的系统评价和荟萃分析
Res Pract Thromb Haemost. 2023 Jun 8;7(5):100201. doi: 10.1016/j.rpth.2023.100201. eCollection 2023 Jul.
2
Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.对推荐剂量的依达赛珠单抗反应不完全：一项系统评价和药代动力学分析
Clin Toxicol (Phila). 2020 Aug;58(8):789-800. doi: 10.1080/15563650.2020.1743846. Epub 2020 Apr 8.
3
Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.依达赛珠单抗用于颅内出血情况下达比加群逆转：文献系统评价
Clin Neurol Neurosurg. 2019 Jun;181:76-81. doi: 10.1016/j.clineuro.2019.04.013. Epub 2019 Apr 15.
4
Retrospective Analysis of the Effectiveness of a Reduced Dose of Idarucizumab in Dabigatran Reversal.达比加群酯逆转剂依达鲁珠单抗低剂量有效性的回顾性分析。
Thromb Haemost. 2022 Jul;122(7):1096-1103. doi: 10.1055/a-1704-0630. Epub 2021 Nov 23.
5
Whole Blood Point-of-Care Testing for Incomplete Reversal With Idarucizumab in Supratherapeutic Dabigatran.达比加群酯超治疗剂量时使用依达鲁单抗完全逆转的全血即时检测
Anesth Analg. 2020 Feb;130(2):535-541. doi: 10.1213/ANE.0000000000004419.
6
Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.达比加群酯拮抗剂依达鲁珠单抗逆转抗凝作用的系统评价。
Am J Ther. 2018 May/Jun;25(3):e333-e338. doi: 10.1097/MJT.0000000000000460.
7
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?在一名多发伤患者中使用艾达赛珠单抗难以逆转达比加群：剂量问题？
Trauma Case Rep. 2021 Feb 10;32:100422. doi: 10.1016/j.tcr.2021.100422. eCollection 2021 Apr.
8
Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?艾达赛珠单抗用于逆转达比加群相关出血：用词不当还是奇迹？
J Emerg Med. 2017 Mar;52(3):341-347. doi: 10.1016/j.jemermed.2016.08.023. Epub 2016 Oct 8.
9
Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.艾达西珠单抗用于达比加群逆转：两例硬膜下血肿患者在急诊科的治疗经验
Trauma Case Rep. 2017 Dec 29;13:46-49. doi: 10.1016/j.tcr.2017.12.003. eCollection 2018 Feb.
10
Assessment of patients post reversal with idarucizumab.评估患者接受依达鲁珠单抗逆转治疗后的情况。
J Thromb Thrombolysis. 2018 Nov;46(4):466-472. doi: 10.1007/s11239-018-1723-1.

引用本文的文献

1
Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran.依达赛珠单抗比达比加群更有效地逆转达比加群酰葡萄糖醛酸的抗凝作用。
Sci Rep. 2025 Jul 1;15(1):21967. doi: 10.1038/s41598-025-08417-0.

本文引用的文献

1
Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.在接受口服抗凝剂治疗的真实出血患者中，凝血酶生成（逆转或未逆转）与（激活的）凝血酶原复合物浓缩物有关。
Thromb Res. 2023 Mar;223:184-193. doi: 10.1016/j.thromres.2023.01.022. Epub 2023 Jan 30.
2
Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.用于治疗大出血的干预措施中止血效果的定义：国际血栓与止血学会抗凝控制分委会的沟通文件
J Thromb Haemost. 2021 Apr;19(4):1112-1115. doi: 10.1111/jth.15222.
3
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.
2021 年国际血液学标准化委员会直接口服抗凝剂实验室检测推荐更新版。
Thromb Haemost. 2021 Aug;121(8):1008-1020. doi: 10.1055/a-1450-8178. Epub 2021 May 30.
4
Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.逆转前达比加群水平可预测依达赛珠单抗在真实世界中的止血效果。
Front Med (Lausanne). 2020 Dec 16;7:599626. doi: 10.3389/fmed.2020.599626. eCollection 2020.
5
Real-world experience with reversal of dabigatran by idarucizumab.idarucizumab逆转达比加群作用的真实世界经验。
Thromb Res. 2021 Jan;197:179-184. doi: 10.1016/j.thromres.2020.11.010. Epub 2020 Nov 10.
6
Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis.对推荐剂量的依达赛珠单抗反应不完全：一项系统评价和药代动力学分析
Clin Toxicol (Phila). 2020 Aug;58(8):789-800. doi: 10.1080/15563650.2020.1743846. Epub 2020 Apr 8.
7
Idarucizumab for dabigatran reversal in daily clinical practice: A case series.达比加群酯逆转剂依达鲁珠单抗在日常临床实践中的应用：病例系列研究。
Eur J Anaesthesiol. 2020 Oct;37(10):874-878. doi: 10.1097/EJA.0000000000001185.
8
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.达比加群酯逆转剂依达鲁单抗在肾功能损害患者中的应用。
J Am Coll Cardiol. 2019 Oct 8;74(14):1760-1768. doi: 10.1016/j.jacc.2019.07.070.
9
The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation.艾达赛珠单抗的（Fab）传奇命运：凸显其对尿蛋白免疫固定的干扰
TH Open. 2019 Sep 16;3(3):e306-e308. doi: 10.1055/s-0039-1697642. eCollection 2019 Jul.
10
Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab.达比加群的持续再分布需要重复使用艾达司珠单抗。
Br J Anaesth. 2018 Aug;121(2):505-508. doi: 10.1016/j.bja.2018.04.025. Epub 2018 Jun 12.